Wren Laboratories

11/08/2025

Proud to Announce: Wren Laboratories is Now ISO 15189 Accredited!

We’re thrilled to share that Wren Laboratories has officially achieved ISO 15189 accreditation — a major milestone affirming our unwavering commitment to quality, precision, and excellence in patient care.

What makes this even more special is how it happened. Our initial gap assessment audit was immediately converted into a full accreditation audit, with no major findings and overwhelmingly positive feedback from the auditors, who described their experience as uniquely impressive and highlighted our “super-human” level of preparedness and expertise.

To quote their note:

“We were truly impressed by your laboratory’s preparedness and your dedication to delivering excellence in patient care.”

Achieving certification in record time underscores the strength of our team, our systems, and our dedication to setting new standards in molecular diagnostics.

A sincere thank you to the entire Wren team — your passion and precision made this possible.

11/08/2025

Exciting News from Wren Laboratories at AMP 2025!

We’re thrilled to announce that Wren Laboratories will be presenting multiple scientific contributions and exhibiting at the AMP 2025 Annual Meeting in Boston, Nov 11-15!

Visit us at Booth #1036 to learn how our advanced mRNA-based molecular diagnostics are transforming precision medicine.

Oral Presentation:
“Novel ML-Enhanced Liquid Biopsy Multigene mRNA Expression for Standard-of-Care and Drug Development”, Friday November 14, 3-3:30pm Innovation Spotlight Stage #3.

Poster Presentations:
Exploring the Saliva Metagenome for Infectious Disease Detection — Fri, Nov 14, 9:15–10:15

Identification of mRNA Biomarkers for PDAC using Comprehensive Data Mining — Fri, Nov 14, 9:15–10:15

Identification of Genetic Alterations in Familial Small Intestinal NETs via Whole Blood DNA Sequencing — Sat, Nov 15, 9:15–10:15

We’re proud to share how Wren’s integrated molecular and bioinformatics platforms are driving next-generation diagnostics for patient care and clinical research.

Looking forward to connecting with colleagues, collaborators, and partners at — see you in Boston!

09/17/2025

Wren proudly supports Prostate Cancer Awareness Month. Learn more about PROSTest® at https://wrenlaboratories.com/our-tests/

05/23/2025

🧬 Wren Laboratories | Booth #37167 | Chicago
We're excited to participate in the 2025 ASCO® Annual Meeting, where we’ll be showcasing how our AI-powered, blood-based mRNA diagnostics are redefining cancer care from early detection to therapy response monitoring and tumor tissue-independent MRD assessment.
📍 Explore how our platform--with less than 0.1% failure rate--is:
• 🧪 Enhancing patient stratification
• 🎯 Predicting treatment response
• 💊 Supporting drug development from discovery to CDx
📖 Learn more by viewing our abstract (Title: Utility of the PROSTest, a novel blood-based molecular assay, versus PSA for prostate cancer stratification and detection of higher grade disease) on the ASCO website.
We look forward to connecting in Chicago!

04/18/2025

Wren Laboratories is Revolutionizing Cancer Research!

We’re excited to be part of the American Association for Cancer Research® (AACR) Annual Meeting 2025.
Wren Laboratories will be showcasing our AI-enhanced liquid biopsy multigene mRNA expression technology—designed to transform cancer research and drug development from discovery to CDx development!
Stop by Booth #2608 to learn how our innovative technology is advancing early-phase trials, enabling patient selection & stratification, and offering reliable monitoring tools for drug effectiveness and for the detection of MRD and tumor recurrence.
Additionally, we’re proud to present three exciting posters that delve deeper into our work:
• Comparative Gene Signature Between NEPC and CRPC Transcriptomics – [Poster # 693; Section #29; Board #26, Day: 27th at 2-5PM]
• Gene Signature to Forecast Lu-PSMA Response in Advanced Prostate Cancer – [Poster # 2354; Section #42; Board #30, Day: 28th at 9AM to 12PM]
• mRNA Expression in Paired Saliva and Blood Samples from Different Cancer Indices – [Poster # 4575; Section #29; Board #28, Day: 29th at 9AM to 12PM]
These presentations will provide valuable insights into our cutting-edge novel technology.
Don’t miss out on the chance to connect with us and explore how we’re shaping the future of oncology. We can’t wait to see you in Chicago!

(AACR is not endorsing this advertisement)

02/21/2025

🩸 Revolutionizing Prostate Cancer Care with PROSTest!

Wren Laboratories is leading the way in prostate cancer detection with PROSTest, AI-enhanced non-invasive liquid biopsy multigene mRNA expression test that offers better diagnostic accuracy, eliminates unnecessary biopsies, and enhances patient outcomes.

PROSTest Key Highlights
✅ 96.0% sensitivity at 99.3% specificity, significantly outperforming traditional PSA testing (91.2% sensitivity, 65.8% specificity)
✅ 94% sensitivity for detecting minimal residual disease (MRD) and recurrence, compared to just 79% for Gallium-PET scans
✅ Only 1mL of blood required, making it a simple and less invasive alternative to traditional biopsy
✅ More accurate than PSA in detecting prostate cancer and monitoring therapeutic response

🩸 PROSTest offers a critical advantage: it eliminates unnecessary biopsies often triggered by elevated PSA levels of 3ng/mL or higher, which can frequently result in false positives. In fact, of the 1 million biopsies performed annually in the U.S. due to elevated PSA, only about 190,000 lead to a diagnosis of clinically significant prostate cancer. With PROSTest, you can get a much more accurate result, potentially avoiding the risks and discomfort of unnecessary biopsies.

Now available under CLIA, CAP, and NYSDOH certifications, PROSTest is offered to both patients and investigators, ensuring more accurate, reliable, and timely prostate cancer diagnostics.

Learn more about how PROSTest is revolutionizing prostate cancer care: https://hubs.la/Q036Dg0l0

Read the full publications at https://hubs.la/Q036Dh5y0

We are committed to advancing precision medicine through cutting-edge mRNA diagnostics, improving cancer care, and accelerating drug development.

02/14/2025

🩸 Wren Laboratories Advances Precision Medicine for Neuroendocrine Tumors!

Diagnosing and managing gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) has long been a challenge. With the critical need for a reliable biomarker, Wren Laboratories has taken a major leap forward!

Introducing NETest 2.0 – our AI-enhanced non-invasive liquid biopsy multigene mRNA expression test that significantly improves the detection and monitoring of NETs.

✅ >95% sensitivity for detecting NETs
✅ >90% accuracy in identifying progressive disease
✅ Enhanced ability to differentiate NETs from other malignancies
✅ Validated in global patient cohorts across the U.S., Europe, Latin America, Africa, and Asia
✅ Continues to offer the PPQ score, previously established in NETest 1.0, which predicts patient response to PRRT with a 98% positive predictive value (PPV) and 93% negative predictive value (NPV)

Powered by machine learning and a refined 51-gene expression algorithm, NETest 2.0 delivers unmatched diagnostic and prognostic accuracy—a game-changer for clinicians and patients alike.

Why does this matter?
Earlier and more precise detection + prediction of response to therapeutics = better treatment and management decisions = improved patient outcomes.

With proven effectiveness in diverse populations, NETest 2.0 is setting a new standard for NET diagnostics.

🩸 Now available under CLIA, CAP, and NYSDOH certifications, the test is being offered to patients and investigators, making cutting-edge NET diagnostics more accessible than ever.

Proudly developed and validated by Wren Laboratories, this breakthrough underscores our commitment to revolutionizing precision oncology!

🔗Read the full publication here: https://hubs.la/Q036Dd3k0

11/11/2024

The Team at Wren Laboratories is spreading awareness of Neuroendocrine Cancer by partnering with patients, providers, and the community to create a global voice for Neuroendocrine cancer! Neuroendocrine cancer is often misdiagnosed for a long time. Learn more about NETCancer and Wren Laboratories blood-based tests that utilize mRNA and AI at > https://hubs.la/Q02XPnhJ0


.0

11/04/2024

Dr. Srinivas Koduru Ph.D our Director of Transcriptomics is getting ready to present his findings in "Assessing Saliva for Cancer Biomarker Discovery: A Liquid Biopsy Approach" To learn how we are transforming cancer detection through mRNA biomarkers visit our website > https://hubs.la/Q02WNX1W0

.0

10/22/2024

Our team is getting ready to present at NANETS Multidisciplinary NET Medical Symposium happening in next month. Be sure to stop by our table to learn how our technology ensures reliable clinical biomarker detection, supporting the early diagnosis and monitoring of cancer. See you in

.0

10/17/2024

Please join us for our next live webinar happening Monday, October 28th at 11a EST! See you there...

🌟 Join Wren Laboratories for an informative webinar on the integration of technologies in clinical trials, revolutionizing biomarker discovery and implementation. Discover non-invasive insights into tumor biology and therapeutic responses, as we explore Wren’s innovative approach to gene signatures.

Dr. Abdel Halim will discuss the clinical applicability of Wren’s novel mRNA gene signatures in enhancing the drug development process, including proof of concept and mechanism studies.

➡️ Learn more + register here: https://buff.ly/4eOkmWE

10/11/2024

to our time at in Boston! We shared how we are unlocking a deeper cancer understanding through Molecular Diagnostics > https://hubs.la/Q02T7p8M0